<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432858</url>
  </required_header>
  <id_info>
    <org_study_id>Prophylactic Antibiotics: ESCR</org_study_id>
    <nct_id>NCT03432858</nct_id>
  </id_info>
  <brief_title>Preoperative Antibiotics for Carpal Tunnel Release Surgery</brief_title>
  <official_title>Endoscopic Carpal Tunnel Release, Infection Incidence, and Prophylactic Antibiotics: Indicated or Kick the Habit?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WellSpan Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>WellSpan Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to determine how effective antibiotics administered prior to&#xD;
      endoscopic carpal tunnel release surgery are in preventing surgical site infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be randomized to a prophylactic IV antibiotic treatment arm&#xD;
      (Vancomycin or Cefazolin) or a placebo IV saline solution. Subjects will be monitored&#xD;
      following surgery for surgical site infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Principal investigator, co-investigators, and participants are blinded to study intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Definitive diagnosis of infection of surgical site -Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infection that have diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infection that have diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infections That Use Tobacco</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that use tobacco products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infections That Use Tobacco</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that use tobacco products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anemia Diagnosis and Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anemia Diagnosis and Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have peripheral artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections that have peripheral artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection and a History of Arthroplasty</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with history of arthroplasty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection and History of Arthroplasty</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with history of arthroplasty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with valvular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with valvular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with single incision ECTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with single incision ECTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with double incision ECTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>Number of patients with surgical site infections with double incision ECTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Last Cortisone Injection</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Last Cortisone Injection</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acuity of Carpal Tunnel Syndrome</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acuity of Carpal Tunnel Syndrome</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin - 1-gram dosing</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High probability (&gt;12 points) on the Carpal Tunnel-6 diagnostic aide&#xD;
&#xD;
          -  Recommendation for carpal tunnel release&#xD;
&#xD;
          -  Capable of providing informed consent/LAR to act on subject's behalf&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients allergic to both penicillin/cephalosporins and vancomycin&#xD;
&#xD;
          -  Patient immobilized with splint or cast&#xD;
&#xD;
          -  Unwilling unable to provide informed consent&#xD;
&#xD;
          -  Children under the age of 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WellSpan Surgery and Rehab Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>WellSpan Health</investigator_affiliation>
    <investigator_full_name>Richard C Trevino, MD</investigator_full_name>
    <investigator_title>Orthopedic Surgeon -WellSpan Orthopedics</investigator_title>
  </responsible_party>
  <keyword>Endoscopic Carpal Tunnel Release</keyword>
  <keyword>Prophylactic Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03432858/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator 1</title>
          <description>Vancomycin: 1-gram dosing</description>
        </group>
        <group group_id="P2">
          <title>Active Comparator 2</title>
          <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Saline Solution: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Procedure canceled/rescheduled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required postop mobilization with splinting</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator 1</title>
          <description>Vancomycin: 1-gram dosing</description>
        </group>
        <group group_id="B2">
          <title>Active Comparator 2</title>
          <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Saline Solution: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="14.10"/>
                    <measurement group_id="B2" value="59.0" spread="15.37"/>
                    <measurement group_id="B3" value="55.8" spread="16.36"/>
                    <measurement group_id="B4" value="57.5" spread="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Surgical Site Infection</title>
        <description>Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection</title>
          <description>Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Surgical Site Infection</title>
        <description>Definitive diagnosis of infection of surgical site -Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection</title>
          <description>Definitive diagnosis of infection of surgical site -Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infection that have diabetes</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infection that have diabetes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infection that have diabetes</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diabetes Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infection that have diabetes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infections That Use Tobacco</title>
        <description>Number of patients with surgical site infections that use tobacco products</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infections That Use Tobacco</title>
          <description>Number of patients with surgical site infections that use tobacco products</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infections That Use Tobacco</title>
        <description>Number of patients with surgical site infections that use tobacco products</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infections That Use Tobacco</title>
          <description>Number of patients with surgical site infections that use tobacco products</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have chronic obstructive pulmonary disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anemia Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have anemia</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anemia Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have anemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anemia Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have anemia</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anemia Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have anemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have peripheral artery disease</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have peripheral artery disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections that have peripheral artery disease</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections that have peripheral artery disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection and a History of Arthroplasty</title>
        <description>Number of patients with surgical site infections with history of arthroplasty</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection and a History of Arthroplasty</title>
          <description>Number of patients with surgical site infections with history of arthroplasty</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection and History of Arthroplasty</title>
        <description>Number of patients with surgical site infections with history of arthroplasty</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection and History of Arthroplasty</title>
          <description>Number of patients with surgical site infections with history of arthroplasty</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections with valvular disease</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections with valvular disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</title>
        <description>Number of patients with surgical site infections with valvular disease</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection</title>
          <description>Number of patients with surgical site infections with valvular disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</title>
        <description>Number of patients with surgical site infections with single incision ECTR</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</title>
          <description>Number of patients with surgical site infections with single incision ECTR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</title>
        <description>Number of patients with surgical site infections with single incision ECTR</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release</title>
          <description>Number of patients with surgical site infections with single incision ECTR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</title>
        <description>Number of patients with surgical site infections with double incision ECTR</description>
        <time_frame>2 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</title>
          <description>Number of patients with surgical site infections with double incision ECTR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</title>
        <description>Number of patients with surgical site infections with double incision ECTR</description>
        <time_frame>6 weeks post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release</title>
          <description>Number of patients with surgical site infections with double incision ECTR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Last Cortisone Injection</title>
        <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
        <time_frame>2 weeks post-operative</time_frame>
        <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Last Cortisone Injection</title>
          <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
          <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Last Cortisone Injection</title>
        <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
        <time_frame>6 weeks post-operative</time_frame>
        <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Last Cortisone Injection</title>
          <description>For patients sustaining surgical site infection, the time from their last cortisone injection</description>
          <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acuity of Carpal Tunnel Syndrome</title>
        <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
        <time_frame>2 weeks post-operative</time_frame>
        <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Acuity of Carpal Tunnel Syndrome</title>
          <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
          <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acuity of Carpal Tunnel Syndrome</title>
        <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
        <time_frame>6 weeks post-operative</time_frame>
        <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator 1</title>
            <description>Vancomycin: 1-gram dosing</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator 2</title>
            <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Saline Solution: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Acuity of Carpal Tunnel Syndrome</title>
          <description>For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome</description>
          <population>No patients sustained surgical site infections and data were not collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks post procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator 1</title>
          <description>Vancomycin: 1-gram dosing</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator 2</title>
          <description>Cefazolin: 2-gram dosing for patients &lt;120 kg 3-gram dosing for patients 120 kg or greater</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Saline Solution: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative splinting</sub_title>
                <description>Subject experienced wrist pain unrelated to wound or procedure.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Associate</name_or_title>
      <organization>WellSpan Health</organization>
      <phone>(717) 851-7634</phone>
      <email>cbush@wellspan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

